Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA Wants To Help Sponsors Generate Evidence CMS Needs, But Won't Be An Intermediary

Executive Summary

FDA-CMS communications are expected to evolve as both agencies look to improve their relationship.

You may also be interested in...

Could NIH Help US FDA Answer More Postmarketing Questions?

FDA Commissioner Robert Califf said pharma should not be the sole entity handling postmarket research.

US FDA’s Califf: Payers Should Ask How They Can Help Answer Clinical Research Questions

Instead of asking why confirmatory trials take so long, the FDA commissioner suggests insurance companies ask what they can do to help answer those questions.

Gene Therapies Without Randomized Clinical Trials: Marks Outlines Rare Disease Development Path

A single-arm trial using a biomarker and animal model could be enough for an accelerated approval, especially in a pediatric rare disease where randomization and placebo controls may not be feasible, the CBER director said.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts